Skip to content

US · SBFM · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Sunshine Biopharma, Inc. (SBFM) intrinsic value and stock valuation

$2.23as of 2026-11-21 · Mkt cap 2.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sunshine Biopharma, Inc. DCF and intrinsic value

InvestorsCraft values SBFM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SBFM’s statements →

Sunshine Biopharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Fort Lauderdale, FL 33301 sunshinebiopharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$36.3M+249.1% 5y CAGRd
20112025
Net income
-$-5.98M
20112025
Free cash flow
-$-5.51M
20112025
Total equity
$23M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$36.3M$34.9M$24.1M$4.35M$230K
Operating income-$-4.48M-$-5.81M-$-4.79M-$-8.67M-$-2.44M
Net income-$-5.98M-$-5.13M-$-4.51M-$-26.74M-$-12.44M
EPSd-$-14.24M-$-73.29M———
Operating cash flow-$-5.33M-$-12.53M-$-8.78M-$-5.25M-$-1.83M
Capital expenditure-$-170K-$-2.32M-$-790K-$-300K-$0.00
Free cash flow-$-5.51M-$-14.85M-$-9.56M-$-5.55M-$-1.83M
Total assets$30.1M$30.6M$27.4M$29.6M$2.2M
Total debt$810K$950K$660K$770K$1.9M
Net debt-$-8.31M-$-8.73M-$-15.63M-$-21.06M-$-150K
Total equity$23M$23.5M$21.2M$21.6M$210K
Cash and short-term investments$9.12M$9.69M$16.3M$21.8M$2.05M
Income statement
20252024202320222021
Revenue$36.3M$34.9M$24.1M$4.35M$230K
Cost of revenue$24.4M$24.2M$15.8M$2.65M$120K
Gross profit$11.9M$10.7M$8.34M$1.7M$110K
Research and development expenses$600K$930K$1.86M$810K$670K
Selling, general and administrative expenses$19.6M$14.9M$10.8M$9.48M$1.87M
Other expenses-$-3.83M$610K$440K$80K$10K
Operating expenses$16.4M$16.5M$13.1M$10.4M$2.55M
Cost and expenses$40.8M$40.7M$28.9M$13M$2.67M
Interest income$280K$500K$810K$520K$0.00
Interest expense$0.00$10K$140K$40K$330K
Depreciation and amortization$330K$220K$150K$30K$10K
Ebitda-$-5.62M-$-5.14M-$-3.82M-$-26.45M-$-12.09M
Operating income-$-4.48M-$-5.81M-$-4.79M-$-8.67M-$-2.44M
Total other income/expenses, net-$-1.47M$440K$670K-$-17.84M-$-10M
Income before tax-$-5.95M-$-5.37M-$-4.11M-$-26.51M-$-12.44M
Income tax expense$20K-$-230K$400K$230K$0.00
Net income-$-5.98M-$-5.13M-$-4.51M-$-26.74M-$-12.44M
Weighted average shares outstanding$420K$70K$0.00$0.00$0.00
Weighted average diluted shares outstanding$420K$70K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$9.12M$9.69M$16.3M$21.8M$2.05M
Net receivables$3.46M$3.87M$2.55M$1.91M$10K
Inventory$13.5M$11.3M$5.73M$3.29M$110K
Total current assets$26.9M$26M$24.9M$27.3M$2.2M
Property, plant and equipment, net$1.34M$1.48M$1.01M$1.15M$10K
Goodwill and intangible assets$1.89M$3.02M$1.44M$780K$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.23M$4.59M$2.46M$2.23M$10K
Total assets$30.1M$30.6M$27.4M$29.6M$2.2M
Accounts payable$5.66M$5.54M$2.59M$2.8M$40K
Short-term debt$220K$210K$120K$120K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.44M$6.31M$5.55M$6.93M$90K
Long-term debt$600K$740K$540K$640K$1.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$600K$740K$590K$990K$1.9M
Capital lease obligations$600K$950K$660K$640K$0.00
Total liabilities$7.04M$7.06M$6.14M$7.92M$1.99M
Common stock$0.00$0.00$30K$20K$0.00
Retained earnings-$-75.02M-$-69.04M-$-63.91M-$-59.4M-$-32.66M
Accumulated other comprehensive income (loss)-$-70K-$-830K$700K$160K-$-20K
Total equity$23M$23.5M$21.2M$21.6M$210K
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$810K$950K$660K$770K$1.9M
Net debt-$-8.31M-$-8.73M-$-15.63M-$-21.06M-$-150K
Cash flow statement
20252024202320222021
Net income-$-5.98M-$-5.13M-$-4.51M-$-26.74M-$-12.44M
Depreciation and amortization$330K$220K$150K$30K$10K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-1.45M-$-5.38M-$-4.42M$3.15M-$-110K
Accounts receivable-$-120K-$-2.34M-$-590K-$-520K-$-10K
Inventory-$-1.64M-$-6.01M-$-2.37M$40K-$-80K
Accounts payable-$-190K$3.98M-$-1.36M$3.36M-$-20K
Net cash provided by operating activities-$-5.33M-$-12.53M-$-8.78M-$-5.25M-$-1.83M
Investments in property, plant and equipment-$-840K-$-2M-$-80K-$-190K$0.00
Acquisitions, net$0.00$0.00$0.00-$-14.35M$0.00
Net cash used for investing activities-$-840K-$-2.32M-$-660K-$-14.62M$0.00
Common stock issued$4.75M$12.1M$4.09M$43.6M$0.00
Common stock repurchased$0.00-$-3.14M-$-540K-$-100K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.75M$9.29M$3.43M$39.5M$2.9M
Net change in cash-$-560K-$-6.61M-$-5.53M$19.8M$1.06M
Cash at end of period$9.12M$9.69M$16.3M$21.8M$2.05M
Operating cash flow-$-5.33M-$-12.53M-$-8.78M-$-5.25M-$-1.83M
Capital expenditure-$-170K-$-2.32M-$-790K-$-300K-$0.00
Free cash flow-$-5.51M-$-14.85M-$-9.56M-$-5.55M-$-1.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sunshine Biopharma, Inc.

        Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.

        CEO
        Steve N. Slilaty
        Employees
        50
        Beta
        1.31

        Explore

        Frequently asked questions

        What is the intrinsic value of Sunshine Biopharma, Inc. (SBFM)?

        InvestorsCraft does not currently publish an intrinsic value for SBFM. How the IC value is calculated.

        Is SBFM undervalued?

        InvestorsCraft does not publish an undervaluation signal for SBFM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.